Bio-Innovation Initiatives

Today, I’m thrilled to share what I believe is the biggest breakthrough in microbiome science for a decade. Nature Magazine, the world's most influential scientific journal, has just published a scientific paper by ZOE's scientists, establishing the first reliable, repeatable, global way to measure the health of an individual’s gut microbiome. It represents the culmination of eight years of work at ZOE. Scientists have been trying to solve this puzzle for more than 20 years, right back to when they first discovered how important our gut microbes are for our health. It’s been achieved only because more than 34,000 ZOE members took part in this research. We’ve known for a long time that the microbiome is linked to cholesterol, inflammation, blood sugar control and even how we store fat. But we’ve never had a clear, evidence-based way to measure how healthy a microbiome actually is. This analysis finally delivers it, revealing a global ranking of microbes that works across populations, diets and environments. The insights are remarkable. Among the top 50 “good microbes” linked with better health, 22 were completely unknown to science until today, and most of the others have never been successfully grown in a lab. We also discovered clear links between these good microbes and health outcomes: healthy individuals carry around 3.6 more of these beneficial species, and people at a healthy weight carry about 5.2 more than those living with obesity. We also found a strong connection to diet. People eating healthier diets consistently have microbiomes that score better on this ranking. What we eat shapes our gut health, and now we can measure this relationship with unprecedented clarity. ZOE was created to enable microbiome research at a scale that traditional science has been unable to fund, and use this research to create actionable advice that can transform our gut health. This is a major milestone in that journey. I’m delighted to say that as a result, this breakthrough science is immediately available for the public to investigate their own microbiome through ZOE’s new Gut Health Test in the UK, and this is coming soon in the US. You can now receive not only a reliable measurement of how healthy your microbiome is as you change their diet, but also discover the health of clusters of gut microbes in your gut affecting metabolism, inflammation and more. To all our amazing ZOE members who have participated in our science: you made this possible. You are transforming our understanding of the microbiome. Thank you so much. I hope you feel as proud and excited as I do. I should note that your research is now published in Nature, which is the ultimate scientific accolade, and you can definitely brag about that with your friends! If you think this science could help others understand their health, I’d love for you to share it. You’ll find links to more details from our findings and access to the paper in the comments.

One twin watches her body fail while her identical sister stays perfectly healthy. Scientists just discovered the difference lives in their gut. Two bacteria turning the brain against itself. Think about that. German researchers recruited 81 pairs of identical twins where only one twin had MS—stripping away genetic confusion to expose what really causes MS. They discovered over 50 bacterial differences between affected and unaffected twins, with Eisenbergiella tayi and Lachnoclostridium species standing out as potential MS triggers. Traditional MS Reality: ↳ 2.8 million people affected worldwide ↳ Cause labeled "multifactorial mystery" ↳ Immune suppressants manage symptoms ↳ Progressive disability often inevitable The Microbiome Discovery: ↳ Specific bacteria enriched in MS twins ↳ Transplanted gut microbes trigger disease in mice ↳ Female mice particularly susceptible ↳ Direct gut-brain-immune connection proven But here's what grabbed me: When researchers transplanted gut bacteria from MS twins into germ-free mice, the animals developed MS-like disease. Not from genetics. Not from environment. From microbes alone. The bacteria from healthy twins? Protected the mice. Even more striking: Eisenbergiella tayi, barely detectable in human samples, became dominant in sick mice. A minor player in our gut turning the brain against itself. What changes everything: ↳ MS risk potentially measurable through stool samples ↳ Targeted antibiotics or bacteriophages possible ↳ Precision probiotics to outcompete harmful strains ↳ Prevention before symptoms, not just management The Multiplication Effect: 1 microbiome test = early risk detection 10 targeted interventions = personalized prevention 100 research centers refining = MS becoming preventable At scale = autoimmune diseases decoded through gut bacteria For decades, families watched one twin deteriorate while the other stayed healthy, wondering why their identical biology diverged. Now we know: the difference might be microscopic residents in their intestines. We spent 150 years treating MS as an inevitable brain disease. Now it might be a treatable gut imbalance. Because when identical DNA produces different diseases based on gut bacteria, you realise: The code for MS isn't just written in our genes. It's growing in our gut. Follow me, Dr. Martha Boeckenfeld for innovations where microscopic discoveries transform human health. ♻️ Share if you believe the next medical revolution lives in our gut, not our pharmacy. Resource: Kleinewietfeld, M., et al. (2024). Specific gut bacteria from multiple sclerosis patients modulate human T cell function and exacerbate symptoms in a mouse model. Proceedings of the National Academy of Sciences, 121(48), e2419689122.

My PhD will focus on something we still only partially understand: the molecular mechanisms linking the oral microbiome, the gut, and neurodegeneration. For years, the scientific and clinical conversation has been centred on the gut–brain axis, often overlooking a critical upstream component. The oral microbiome has largely remained at the margins of this discussion, despite growing evidence that it plays a far more central role than previously assumed. This recent review brings this into sharper focus by showing that oral dysbiosis is not confined to the oral cavity but can actively contribute to systemic and neural processes. Several periodontal pathogens are able to disseminate beyond their local environment, influencing immune regulation and promoting inflammatory cascades that extend to the brain. What is particularly striking is that these mechanisms converge on pathways we already recognise as central to neurodegenerative and neuropsychiatric disorders, including microglial activation, cytokine release, and protein misfolding processes associated with Alzheimer’s and Parkinson’s disease. This shifts the perspective from isolated associations to a more integrated biological framework. The oral microbiome is not simply an additional variable, but part of a continuous system that interacts with the gut, the immune system, and neuroendocrine pathways such as the HPA axis. These interactions form a network in which microbial ecosystems across different body sites contribute to a shared inflammatory and metabolic landscape. What becomes increasingly difficult to justify is the way we continue to approach these domains separately. Oral health, gut health, and brain health are still often treated as distinct areas, both in research and in clinical practice. Yet the biology suggests otherwise. These systems are interconnected, and their interactions may be key to understanding not only disease progression but also potential points of intervention. This is precisely where my work is directed: moving beyond descriptive associations to identify the molecular signals that link these microbial ecosystems to neuroinflammatory processes. The goal is not simply to confirm that a connection exists, but to understand how it operates, and whether it can be meaningfully targeted. If these mechanisms are clarified, oral dysbiosis may no longer be seen as a secondary feature or a coincidental finding, but as a modifiable contributor to neurodegeneration. That shift has significant implications, both for how we conceptualise these conditions and for how we approach prevention and intervention. We are still at an early stage in connecting these layers, but one conclusion is becoming increasingly clear. Brain health cannot be fully understood without considering the broader microbial systems that influence it. #parkinsondisease #oralmicrobiome #gutmicrobiome #neurodegeneration https://lnkd.in/echFjvad

“Beyond Food vs Fuel: The Next Ethanol Revolution” The global energy transition is at a turning point. For decades, first-generation ethanol—derived from corn, sugarcane, and grains—has dominated the biofuel landscape. While it helped us take the first step toward renewable fuels, it also brought unintended challenges: food vs. fuel debates, modest climate benefits, and limited efficiency. Now, the future belongs to next-generation ethanol. By tapping into agricultural residues, forestry waste, energy grasses, and even municipal solid waste, 2G ethanol not only eliminates the food security concern but also transforms waste into value. The result? Higher greenhouse gas savings, stronger circular economies, and fuels that can power aviation, shipping, and heavy transport sustainably. Technologies like pretreatment & enzymatic hydrolysis, co-fermentation with engineered microbes, consolidated bioprocessing, and thermochemical pathways are no longer just lab experiments—they are powering commercial-scale plants across India, the U.S., Europe, Brazil, and Canada. From Indian Oil’s Panipat 2G ethanol refinery to LanzaJet’s Freedom Pines SAF facility in Georgia, these projects prove the economics and environmental benefits are real. The business case is clear: companies sticking only to 1G ethanol will be left behind, while those investing in next-generation biofuels will capture new markets, policy incentives, and global leadership in sustainability. 🚀 The question isn’t if but when the shift will happen. Those who act now will define the biofuel economy of the future. Read my article here: Beyond the Food vs Fuel Debate: Why Companies Must Bet on Next-Generation Ethanol for a Sustainable Biofuel Future!! 💬 I’d love to hear your feedback and perspectives—where do you see the biggest opportunities for next-gen ethanol?

A new Nature Microbiology study suggests the gut microbiome may help determine how much fat from a meal ever reaches the bloodstream. Researchers gave isotope-labeled dietary fats to mice with and without gut microbes. The difference was striking: Mice with a microbiome had up to 12 times more fat left inside the intestine and absorbed substantially less into circulation. The microbes were not simply “digesting” the fat. They triggered a chain reaction involving the liver and bile, changing the molecules needed to form micelles, the tiny vehicles that carry dietary fat to the intestinal wall for absorption. In other words, the microbiome may not just respond to what we eat. It may help decide what our body actually extracts from it. That could eventually help explain why two people can eat the same meal and have very different metabolic responses. Important caveat: this was a mouse study. It does not mean a probiotic can block fat absorption or that the microbiome overrides total calorie intake. But it challenges one of nutrition’s simplest assumptions: Food consumed ≠ nutrients absorbed. The real equation may be: Food × human biology × microbial function. We spend enormous effort measuring what goes into the mouth. Maybe we should pay more attention to what actually reaches the bloodstream.

In June 2025, Lucy Therapeutics closed its doors after seven years. The science worked. Multiple animal models showed positive results. The company never got to test its drugs in humans. Its founder wrote: "Even if the science is working, the environment surrounding our biotech ecosystem is not." She's not alone. 39% of smaller biotechs now have less than one year of cash remaining. BCG's 2026 biopharma report notes that numerous transformative treatments in cell and gene therapy have struggled not because of the science, but because of go-to-market challenges. A recent peer-reviewed study found that biotech-pharma partnerships most often falter not due to scientific failure, but because of structural and operational misalignment. The pattern is consistent. The science advances. The operational architecture doesn't keep up. Every biotech founder I speak with can name their lead molecule, their regulatory pathway, and their next funding milestone. Almost none can name the person accountable for their operational architecture. Not the science. The system around the science. The CDMO relationships. The technology partnerships. The platform licensing decisions. The regulatory strategy that has to hold together across all of them. In early-stage biotech, this system grows organically. A CDMO gets selected because someone knew someone. A platform partnership gets structured by the BD lead. A licensing deal gets negotiated by the CEO between fundraising calls. Each decision makes sense in isolation. None of them were designed as a system. Then the programme advances. And the questions compound. Does our CDMO's quality culture match our regulatory pathway? Does our licensing structure allow us to control manufacturing decisions downstream? If a partner changes strategy, what happens to our supply chain? Is our operational story investable, or is it a collection of contracts that nobody has stress-tested as a whole? In most biotechs, these questions don't have an owner until something breaks. A tech transfer fails. A partnership stalls. An investor asks a question in diligence that nobody prepared for. The reason this role doesn't exist in most early-stage companies isn't that founders don't see the need. It's that the need doesn't map to a traditional job title. It sits between science, business development, manufacturing, and regulatory. It's an ongoing accountability that needs to live inside the company's decision-making. The format varies. What matters is the function: someone who holds the operational narrative together before anyone else is forced to examine it. Who owns your operational architecture? If the answer takes more than five seconds, that's the gap. #Biotech #COO #PharmaManufacturing #SeriesB #Biopharma

Can we replace coal with a carbon-negative biofuel? Building on conversations from #COP28, I explore an innovation that has the potential to revolutionize how we think about #sustainable #energy in my newest Forbes article: carbon-negative #biofuel. This technology not only offers a promising alternative to coal but also actively removes carbon dioxide from the atmosphere— a critical step in the fight against #climatechange. Transitioning to a cleaner energy future calls for bold ideas, scalable solutions, and cross-sector collaboration. One such bold idea has been developed by the start-up NextFuel AB, which generates briquettes of fuel using a variety of feedstocks, from sugarcane leaves to elephant grass. Ultimately, NextFuel envisions a world in which much of the agricultural waste in the local region is recycled and used for generating biofuel through torrefaction - quite exciting I find. Read more here:

Episode 40 of the Coworking Chronicles has us traveling to visit The Engine, Part 6… The Engine is an incubator & accelerator supporting Tough Tech, the transformational science and engineering that solves the world’s most important challenges. We caught up with Parisa Farzam, Ph.D. from Oxyverse, Daniel Montoro from TenSixty Biosciences, and Prakash Rao, Ph.D MBA & Mike Neil from BioVergence on this segment.. 🏗️ What are they building? 🏗️ 🧠 Oxyverse is building a wearable brain monitor for patients with neurocritical conditions. Their device gives clinicians real-time information about brain health so they can intervene in scenarios where every second matters. 💊 TenSixty Biosciences is developing next-gen antibody-drug conjugates (ADCs) for difficult-to-treat cancers. Their platform identifies targets that others don't see, then turns those into new drugs 📈 BioVergence is rethinking how biotech startups get funded. Instead of investing at the company level, their model lets investors focus capital on a specific asset within a company, avoiding dilution across a broader portfolio 🤝 How can the Boston ecosystem help and who have they learned from? 🤝 🧠 Parisa Farzam, Ph.D. at Oxyverse is now working with clinicians to launch pilots after strong preliminary data. In Parisa's words "Brain death is silent, we sound the alarm!" She's watching Polyose Bio, an Engine company converting food waste into high-demand polymers. 💊 Daniel Montoro at TenSixty Biosciences is in late preclinical development with strong in-vitro data and is focused on bringing together the right partners and capital to move into the clinic. ImmunoGen, Inc., which spent 30 years struggling through the right parameters to make this entire drug class work, has influenced him the most! 📈 Prakash Rao, Ph.D MBA & Mike Neil at BioVergence are setting up operations in Switzerland this year and building both the investor base and asset pipeline globally, with a particular focus on late preclinical and Phase I companies where milestones can be monetized faster. They're watching AI-based drug discovery companies, both in Boston and globally, that are making it easier to identify promising assets faster. Awesome visit to The Engine. Thanks to their team - Emily Knight, Katherine Otway Londergan & Rachael Faust - and all our participants. Tough Tech in Boston is in GREAT hands! And we’re just getting started covering it at MGMT Boston!

In August, biotech and pharma companies laid off 19,000 people, a 142% increase vs. August 2024 and the highest of any sector. Biotech just had one of its most damaging months in years. This excellent article by Boston Globe Media's Kara Miller illustrates the human and strategic cost. Take NextRNA: A Boston startup advancing non-coding RNA, backed by Bayer: When financing tightened and a July data package slipped, all 27 employees, including the founder-CEO, were let go. They are not alone. Kojin Therapeutics, Abata Therapeutics, iTeos, and others have shut down or cut deeply. Entire pipelines in oncology, neuro, immunology, and rare disease may never reach patients, not because the science failed, but because the environment did. Industry leaders quoted in the article highlight what’s at stake: • Founders who spent 5–7 years advancing programs can no longer finish the R&D cycle. • Thousands of experienced scientists are now navigating one of the toughest job markets in biotech’s history. • The knowledge embedded inside early teams, the hardest thing to rebuild disappears instantly. • Universities face financial strain and tighter immigration pathways, limiting the next generation of scientific talent. • The US downturn coincides with a rapidly strengthening biotech ecosystem in China, shifting where discovery and development are happening. For hubs like Boston, this is not abstract. Biotech is a major economic engine. Persistent shutdowns mean fewer high-paying jobs, less lab demand, and a potential outflow of talent. The long-term implication is clear: If early-stage biotech weakens, the entire innovation pipeline weakens. Large pharma depends on these companies to refill portfolios, especially heading into the 2028–2030 patent cliff. Signals for leadership teams: 1. Protect the core program: Prioritize assets with the strongest regulatory logic and payer rationale. 2. Build optionality early: Regional licensing, structured partnerships, and royalty-based capital extend runway without relying solely on equity markets. 3. Treat knowledge as a strategic asset: Codify scientific decisions, CMC logic, & development frameworks so progress is not lost during downturns. 4. Stay BD-ready: Clean IP, validated CMC, & a coherent value story shorten diligence and materially improve deal outcomes. 5. Track geopolitical shifts: If early US innovation contracts while China accelerates, the center of gravity for drug discovery may shift faster than expected. There are signs that the "biotech winter" is ending. That is good news. However, the US biotech sector needs to quickly become more efficient if it is to compete globally. Time to market remains long, costs high, and risks high. Driving efficiency in the system is essential to its survival in the long term. Unless companies protect their scientific core and stay transaction-ready, this cycle could define the next decade of medicines.

Biomethane/ Biogas Innovations: 🟦 As someone studying the viability of hydrogen, biogas, and biomethane as clean fuels, I’ve been diving deep into how these fuels can secure our energy future. While biomethane currently meets only 0.2% of global gas demand, the potential is staggering. New IEA 2025 assessments show we could produce nearly 1 trillion cubic meters annually from sustainable waste. 🟦 Why does this matter? Beyond decarbonization, biogases provide "dispatchable" clean power (it’s there when the sun isn't shining or there is no wind!) and valuable co-products like biofertilizers. While production costs are currently higher than fossil gas, the economic case becomes undeniable when we factor in carbon pricing and local energy security. 🟦 What is Biomethane/ Biogas? What is Biogas? It’s a mixture of methane (45% to 75%) and CO2 created by breaking down organic matter in oxygen-free environments (anaerobic digestion). We capture this from biodigesters, landfills, and wastewater treatment plants. What is Biomethane? It's "Renewable Natural Gas." By "upgrading" biogas (removing the CO2 and contaminants) or through the thermal gasification of woody biomass, we get a high-purity fuel. It’s chemically identical to natural gas, meaning it works in our existing pipelines, vehicles, and boilers without needing new infrastructure. 🟦 The Sustainability Factor To ensure we aren't competing with food security, the focus is on sustainable feedstocks: a- Agricultural residues (manure and crop husks). b- Biowaste (food waste and sewage sludge). c- Sequential cropping (intermediate crops that actually improve soil health). However, the transition from a niche contributor to a pillar of a circular energy economy require smarter policy and better management of methane leaks. 🟦 Innovation: Many biogas supply chains are mature, several new technologies could boost efficiency and output. Here is a summary of the key innovations: a- Biochar Integration: Enhances anaerobic digester performance by increasing methane production, stabilizing the system, and reducing retention times. b- Biomethanation: Uses biological organisms and onsite hydrogen (from electrolysers) to potentially increase methane yields by over 50% compared to traditional separation methods. c- Two-Phase Anaerobic Digestion: Separates digestion into two stages to allow for: 1- Higher production from smaller reactor footprints. 2- Greater process stability and control. 3- Improved ability to scale production based on local energy demand. d- Microbial Electrolysis Cells (MECs): uses microbes to convert wet organic matter into hydrogen and methane. When integrated with anaerobic digestion, MECs can double yields in lab settings by improving feedstock degradation and converting more CO2 into methane. Reference: IEA Outlook for Biogas and Biomethane 2025 https://lnkd.in/esijNmyn This post is for educational purposes only.